News

Servier and Oncodesign have selected a LRRK2 inhibitor as their partnership program’s lead candidate for Parkinson’s disease and plan to start regulatory preclinical safety studies soon. A Phase 1 clinical trial is expected to begin in 2022. “We are particularly pleased with, and proud of, these results obtained…

In Parkinson’s disease, DNA that leaks out of mitochondria — small organelles that generate energy — leads to cell death and inflammation, according to a new study. The finding indicates that getting rid of this mitochondrial DNA could be a promising therapeutic strategy. The study, “Cytosolic dsDNA of…

The asymmetric loss of dopamine-producing, or dopaminergic, neurons in the brains of people with Parkinson’s disease may determine the severity of patients’ motor and cognitive symptoms, a study suggests. Such differences in the loss of these dopaminergic neurons — a characteristic feature of Parkinson’s — may explain the contrast…

Two years of continuous treatment with apomorphine as an under-the-skin infusion safely preserved quality of life and effectively eased motor fluctuations in people with advanced Parkinson’s disease, according to a single-center, real-life study in France. Notably, patients with poor life quality before starting with continuous apomorphine were more likely to improve in…

Gut inflammation could play a critical role in the onset and progression of Parkinson’s disease, a preclinical study shows. Specifically, this type of inflammation triggered the accumulation of alpha-synuclein protein clumps in the nerves lining the colon of a mouse model of…

Caraway Therapeutics is partnering with AbbVie to develop and market Caraway’s small molecule therapies targeting TMEM175, a potassium ion channel implicated in Parkinson’s disease and other neurodegenerative disorders. TMEM175 is present in lysosomes — tiny compartments in cells containing enzymes that break down unwanted cell parts, digesting and…

One month of non-invasive vagus nerve stimulation (nVNS), administered at home using a hand-held device by electroCore, improved walking and motor abilities, and eased freezing of gait in adults with Parkinson’s disease, according to data from a small clinical trial. Freezing of gait refers to a patient’s feeling for…

The U.S. Food and Drug Administration (FDA) has rejected an application from Verily Life Sciences that sought to add a Parkinson’s disease symptom assessment tool to the company’s clinical research-focused smartwatch. In its response letter, the FDA said there was not enough evidence that the criteria evaluated…

Oral doses of silibinin — a plant compound sold as a dietary supplement — were found to lessen cognitive impairment in a mouse model of Parkinson’s disease. It worked, according to researchers, by preventing neurodegeneration in the hippocampus, a brain region associated with cognitive function. These neuroprotective effects…

The first patient has been dosed in a still-recruiting Phase 1 clinical trial testing DA01, an investigational cell therapy for Parkinson’s disease. A separate Phase 1 trial of a potential gene therapy for Parkinson’s is also recruiting eligible patients in the U.S., according to a press release from…